Jeffrey Sosman

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi request reprint Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group
    Vernon K Sondak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 20:2058-66. 2002
  2. ncbi request reprint Molecular targets in melanoma from angiogenesis to apoptosis
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 12:2376s-2383s. 2006
  3. ncbi request reprint Opportunities and obstacles to combination targeted therapy in renal cell cancer
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Clin Cancer Res 13:764s-769s. 2007
  4. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
  5. doi request reprint Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
    Kerstin Trunzer
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 31:1767-74. 2013
  6. pmc A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430
    Jeffrey A Sosman
    Vanderbilt University School of Medicine, Department of Medicine, Nashville, Tennessee, USA
    Cancer 117:4740-06. 2011
  7. pmc Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    N Engl J Med 366:707-14. 2012
  8. ncbi request reprint Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy
    Jeffrey A Sosman
    Department of Medicine, Division of Hematology Oncology, Vanderbilt University School of Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232, USA
    J Am Soc Nephrol 14:2695-702. 2003
  9. ncbi request reprint Melacine: an allogeneic melanoma tumor cell lysate vaccine
    Jeffrey A Sosman
    Melanoma Program, Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Nashville, TN 37027, USA
    Expert Rev Vaccines 2:353-68. 2003
  10. pmc Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:2292-8. 2008

Research Grants

Detail Information

Publications44

  1. ncbi request reprint Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group
    Vernon K Sondak
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 20:2058-66. 2002
    ..Patients with clinically negative nodes constitute over 85% of new melanoma cases. There is no adjuvant therapy for intermediate-thickness, node-negative melanoma patients...
  2. ncbi request reprint Molecular targets in melanoma from angiogenesis to apoptosis
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 12:2376s-2383s. 2006
    ..Investigators in this field will need to carefully plan these trials so that at the end of the day, we learn from both the failures and successes of targeted therapy...
  3. ncbi request reprint Opportunities and obstacles to combination targeted therapy in renal cell cancer
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Clin Cancer Res 13:764s-769s. 2007
    ..Many of the above strategies are ongoing and will require careful phase 1 determination of toxicity and even more rigorous phase 2 analysis before moving onto phase 3 trials...
  4. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
    ....
  5. doi request reprint Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
    Kerstin Trunzer
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 31:1767-74. 2013
    ..The data suggest that inhibition downstream of BRAF should help to overcome acquired resistance...
  6. pmc A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430
    Jeffrey A Sosman
    Vanderbilt University School of Medicine, Department of Medicine, Nashville, Tennessee, USA
    Cancer 117:4740-06. 2011
    ....
  7. pmc Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    N Engl J Med 366:707-14. 2012
    ..The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial...
  8. ncbi request reprint Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy
    Jeffrey A Sosman
    Department of Medicine, Division of Hematology Oncology, Vanderbilt University School of Medicine, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232, USA
    J Am Soc Nephrol 14:2695-702. 2003
    ....
  9. ncbi request reprint Melacine: an allogeneic melanoma tumor cell lysate vaccine
    Jeffrey A Sosman
    Melanoma Program, Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Nashville, TN 37027, USA
    Expert Rev Vaccines 2:353-68. 2003
    ..This finding must now be confirmed in a large perspective observation-controlled clinical trial to solidify the role of Melacine as an effective cancer vaccine in melanoma...
  10. pmc Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:2292-8. 2008
    ..We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial...
  11. doi request reprint Combination targeted therapy in advanced renal cell carcinoma
    Jeffrey Sosman
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 777 Preston Building, Nashville, TN 37232 6307, USA
    Cancer 115:2368-75. 2009
    ..Once tolerability for combination regimens has been established, it will be critical to design informative phase 2 trials and address the benefit of combination versus sequential therapy...
  12. ncbi request reprint Inside life of melanoma cell signaling, molecular insights, and therapeutic targets
    Jeffrey A Sosman
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232, USA
    Curr Oncol Rep 11:405-11. 2009
    ....
  13. doi request reprint Improving outcomes in patients with advanced renal cell carcinoma
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232, USA
    Expert Rev Anticancer Ther 8:481-90. 2008
    ..Further studies are needed to determine whether combinations and/or sequencing of these targeted agents can further improve outcomes...
  14. ncbi request reprint Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma
    Thomas F Gajewski
    Department of Medicine, University of Chicago, IL 60637, USA
    Clin Cancer Res 11:7861-5. 2005
    ..We postulated that the addition of O(6) benzylguanine (O(6)BG), a potent inactivator of AGT, would improve the clinical response to BCNU in melanoma...
  15. ncbi request reprint Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 23:7889-96. 2005
    ....
  16. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  17. ncbi request reprint Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome
    Jeffrey A Sosman
    Vanderbilt University, Nashville, TN, USA
    J Clin Oncol 20:2067-75. 2002
    ..This study investigated whether class I antigen expression impacted relapse-free survival (RFS) after adjuvant therapy with this vaccine...
  18. doi request reprint B-RAF inhibitors: an evolving role in the therapy of malignant melanoma
    Cynthia Shepherd
    Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232, USA
    Curr Oncol Rep 12:146-52. 2010
    ..This review updates the status of BRAF inhibitors in melanoma and what may be on the horizon...
  19. ncbi request reprint Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma
    Katayoun I Amiri
    Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Cancer Res 64:4912-8. 2004
    ..Our data indicate strongly that bortezomib in combination with chemotherapeutic agents should be studied additionally for the treatment of melanoma...
  20. ncbi request reprint A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
    Michael B Atkins
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 8:3075-81. 2002
    ..Tumor staging included torso computed tomography scans and brain magnetic resonance imaging pretreatment, after cycle 4 and then every 3 months for 2 years. Torso computed tomography scans were also performed after cycle 2...
  21. doi request reprint Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    David F McDermott
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
    J Clin Oncol 26:2178-85. 2008
    ..This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma...
  22. pmc Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials
    Christine M Lovly
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 7:e35309. 2012
    ....
  23. ncbi request reprint Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690
    John M Kirkwood
    Department of Medicine, University of Pittsburgh, Pennsylvania, USA
    Cancer 95:1101-12. 2002
    ....
  24. doi request reprint Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 113:2139-45. 2008
    ..The authors tested the efficacy of a regimen including TMZ, thalidomide, and whole brain radiation therapy (WBRT) in patients with brain (CNS) metastases from melanoma...
  25. pmc A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets
    Yingjun Su
    Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee 37027, USA
    Clin Cancer Res 16:348-57. 2010
    ....
  26. pmc Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, Division of Hematology Oncology, 2160 South First Avenue, Maywood, IL 60153, USA
    Cancer 116:424-31. 2010
    ..We conducted a multicenter phase 2 trial to better define the clinical efficacy of thalidomide and temozolomide and the immune modulatory effects of thalidomide, when combined with temozolomide, in patients with metastatic melanoma...
  27. ncbi request reprint Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide
    Supriya Perambakam
    Department of Medicine, Section of Hematology Oncology, University of Illinois, Room 3150, Molecular Biology Research Building, 900 South Ashland Avenue, Chicago, IL 60607, USA
    Cancer Immunol Immunother 55:1033-42. 2006
    ..DTH-derived T cells exhibited PSA-peptide-specific cytolytic activity and predominantly expressed a type-1 cytokine profile...
  28. ncbi request reprint Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy
    Ken Wyman
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer 106:2005-11. 2006
    ..Signal transduction via c-kit, PDGFR-alpha, and PDGFR-beta has been demonstrated in malignant melanoma...
  29. doi request reprint Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Genitourin Cancer 5:427-32. 2007
    ....
  30. ncbi request reprint The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study
    Kenneth R Hande
    Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA
    Clin Cancer Res 12:2834-40. 2006
    ..ABT-751 was investigated in this phase 1 trial designed to assess its maximum tolerated dose (MTD), dose-limiting toxicity (DLT), tolerability, and pharmacokinetics...
  31. pmc Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
    A Craig Lockhart
    Vanderbilt University Medical Center, Nashville, TN, USA
    J Clin Oncol 28:207-14. 2010
    ..This phase I study was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of VEGF Trap administered intravenously (IV) every 2 weeks...
  32. ncbi request reprint Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine
    Vernon K Sondak
    Division of Surgical Oncology, University of Michigan Health System, 3306 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0932, USA
    Semin Cancer Biol 13:409-15. 2003
    ..A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed...
  33. ncbi request reprint When will melanoma vaccines be proven effective?
    Jeffrey A Sosman
    J Clin Oncol 22:387-9. 2004
  34. ncbi request reprint Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:667s-670s. 2007
    ....
  35. ncbi request reprint Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
    ..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)...
  36. ncbi request reprint Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
    J Immunother 30:839-46. 2007
    ..Despite clinical efficacy, the study was closed prematurely owing to excess toxicity. Although all serious adverse events resolved, this degree of toxicity is unacceptable for an outpatient treatment regimen...
  37. doi request reprint Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  38. ncbi request reprint Biological drug duo delivers one-two tumor punch
    Jeffrey A Sosman
    Nat Med 9:649-50. 2003
  39. ncbi request reprint Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development
    Brian I Rini
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    BJU Int 96:286-90. 2005
  40. ncbi request reprint Sunlight and reduced risk of cancer: is the real story vitamin D?
    Kathleen M Egan
    J Natl Cancer Inst 97:161-3. 2005
  41. ncbi request reprint Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer
    Supriya Perambakam
    Section of Hematology Oncology M C 734, Room 3150, Molecular Biology Research Building, 900 S Ashland Avenue, The University of Illinois at Chicago, Chicago, IL 60607, USA
    Cancer Immunol Immunother 51:263-70. 2002
    ..The results indicate that the PSA 146-154 peptide emulates a naturally processed and presented peptide epitope of PSA that is within the T-cell repertoire of HLA-A2(+)patients with CaP...
  42. ncbi request reprint Targeting multiple genetic aberrations in isolated tumor cells by spectral fluorescence in situ hybridization
    Marilyn L Slovak
    Department of Cytogenetics, City of Hope National Medical Center, Duarte, CA 91010, USA
    Cancer Detect Prev 26:171-9. 2002
    ..Simultaneous detection of more than three chromosomal or gene targets should increase the overall power of molecular cytogenetics by permitting detection of multiple genetic aberrations at the single cell level...
  43. ncbi request reprint Innovations and challenges in melanoma: summary statement from the first Cambridge conference
    Michael B Atkins
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2291s-2296s. 2006
    ..and Challenges in Melanoma, chaired by Michael Atkins and cochaired by Ulrich Keilholz, John Kirkwood, and Jeffrey Sosman, was held July 15 to 16, 2005, in Cambridge, Massachusetts...
  44. doi request reprint Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431)
    Stephen R Moore
    City of Hope, Duarte, California 91010, USA
    Clin Cancer Res 14:2927-35. 2008
    ..The concordance between molecular cytogenetic techniques used to determine CNA has not been evaluated on a large set of loci in malignant melanoma...

Research Grants6

  1. Overcoming DC defects in cancer patients by VEGF trap
    Jeffrey Sosman; Fiscal Year: 2005
    ..Thereby, the correlative studies described here may lead to the establishment of VEGF inhibition, VEGF Trap, specifically, as an approach to combine with and enhance cancer immunotherapy. ..
  2. Clinical Investigation in Tumor Immunotherapy
    Jeffrey Sosman; Fiscal Year: 2006
    ..By combining my efforts to merge laboratory efforts and immunologic endpoints with strong clinical trial design, I believe clinical research can better move tumor immunotherapy forward in a more rationale way. ..
  3. Overcoming DC defects in cancer patients by VEGF trap
    Jeffrey Sosman; Fiscal Year: 2005
    ..Thereby, the correlative studies described here may lead to the establishment of VEGF inhibition, VEGF Trap, specifically, as an approach to combine with and enhance cancer immunotherapy. ..
  4. Inhibition of nf-kb signaling in melanoma therapy
    Jeffrey Sosman; Fiscal Year: 2005
    ..Abstract Not Provided ..
  5. (IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
    Jeffrey A Sosman; Fiscal Year: 2010
    ..A better understanding of the basis for effective or even the mechanism underlying ineffective therapy will be critical to understanding how to proceed in the development of this drug and may influence the evaluation of other drugs. ..